Edian takes your sponsor’s RFI or RFP email and creates a polished proposal and a pricing workbook in the sponsor’s required format.
Contents
Parts
Enrolment completes in 22 months, 6 later than the RFP’s 16
We will randomise 900 patients at 120 sites in8 countries. First patient in is planned for 26 July 2027, and the last patient is in by May 2029. Figure 4.3 shows the forecast and its likely range.
Just over two in five patients come from US sites:44%, against the sponsor’s minimum of 40%.
Figure 4.3
| Country | Sites | Rate | A month |
|---|---|---|---|
| United States | 48 | 0.46 | 22.1 |
| Germany | 18 | 0.44 | 7.9 |
| France | 12 | 0.42 | 5.0 |
| Spain | 12 | 0.44 | 5.3 |
| Italy | 10 | 0.39 | 3.9 |
| Poland | 8 | 0.27 | 2.2 |
| United Kingdom | 8 | 0.35 | 2.8 |
| Netherlands | 4 | 0.35 | 1.4 |
| All countries | 120 | 50.6 |
Done. Everything is ready for Friday 27 November. Click any number to see how it was worked out.
Enrolment takes 22.3 months, so the proposal says 22. Most of it comes from the US rate, 0.46 patients a site a month, set from 6 comparable trials. Recruitment 6 trials
Each country’s sites times its rate gives 50.6 patients a month. Change a number in the table, and all 4 places update.
Nothing changes in the proposal until you apply.
Applied to Realistic
Each change is marked in purple on the page. One sentence needs new words.
Our enrolment forecast: 900 patients in 22 months, with its likely range, against the 16 months in the RFP.
Technical proposal for Aldermoor Therapeutics
Lanvetirom in NASH, Phase III
A 72-week, randomised, double-blind, placebo-controlled Phase III study of lanvetirom in adults with NASH and stage F2 to F3 fibrosis
Confidential. Prepared by Pellworth Clinical Research for Aldermoor Therapeutics only. Please don’t share it beyond Aldermoor without our written consent.
Prepared in EdianCreate a proposal
Built with advisors formerly at
Backed by
Contact
Discuss how your bid team works and learn more about Edian.